Paris, France – Reported by Elite Traveler, the Private Jet Lifestyle MagazineBlancpain is delighted to inaugurate, within its Boutique on the Place Vendôme, Paris, an incredible exhibition dedicated to one of its emblematic models, the Fifty Fathoms. Assembled thanks to the generosity of numerous collectors from around the world, this line- up features an impressive array of the various Fifty Fathoms created by Blancpain from 1953 to the present day. It can be viewed on Place Vendôme in Paris until November 2010, before travelling to China and the United States.This exhibition composed of more than 60 models retraces the history of the Fifty Fathoms, from its creation in 1953 at the request of the French Navy combat divers unit, through to this year’s launch of the Complete Calendar Flyback Chronograph, moon phases. Visitors will thus be able to journey through time by following the evolution of this iconic watch and discovering some extraordinary anecdotes relating to it.This world-exclusive stellar commemoration is part of a program of events organized by Blancpain to celebrate its 275th anniversary and to mark the opening last spring of its new Parisian boutique. A genuine Embassy of the Manufacture from Le Brassus located on one of the world’s most prestigious squares, this boutique presents Blancpain’s finest creations in a setting pervaded by the brand heritage and know-how. This area is designed to take each visitor on a journey to the heart of fine watchmaking as embodied by Blancpain. The exhibition dedicated to the Fifty Fathoms could thus not have dreamt of a finer showcase in which to reveal its splendors.Blancpain also wishes to thank the many collectors from around the world who have responded to its call. Their generosity and their passion for horology have enabled it to pay this vibrant tribute to the destiny of the Fifty Fathoms, the first modern diver’s watch in horological history.www.blancpain.com
Source:https://www.hebrewseniorlife.org/ Reviewed by James Ives, M.Psych. (Editor)Aug 30 2018A paper titled “Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomization study” appeared today in the British Medical Journal. The paper reports findings from a large international collaboration that identified 15 variations in the genome that are related to the risk of suffering bone fractures, which are a major healthcare problem affecting more than 9 million persons worldwide every year. The study provides evidence against a causal effect of several proposed clinical risk factors for fractures, including diabetes, rheumatoid arthritis, vitamin D, as well as others. These findings strongly suggest that treatments aimed at increasing bone strength are more likely to be successful in preventing fractures than widespread supplementation of calcium and vitamin D or targeting other risk factors that were not found to mediate the disease.This study was made possible through a team of researchers from the U.S., Europe, Canada, Asia and Australia who formed the largest effort to date investigating the genetics of osteoporosis and fracture risk. The study team included researchers from the Institute for Aging Research at Hebrew SeniorLife–among them, co-senior author Douglas P. Kiel, M.D., M.P.H., Director of the Musculoskeletal Research Center. The study sample was comprised of 185,057 cases of bone fractures and 377,201 controls who were part of the Genetic Factors for Osteoporosis (“GEFOS”) Consortium, the UKBiobank Study and the 23andMe biotech company.This first genome-wide association study (GWAS) of fracture risk provides insight into the biologic mechanisms leading to fractures. Most importantly all of the identified genomic regions found to be associated with fracture have also been previously found to be associated with variation in bone mineral density (BMD), one of the most important risk factors for fracture. Based on this finding, the study team performed an additional analysis called “Mendelian Randomization,” that uses genetic information to determine causal relations between risk factors and disease outcomes. The Mendelian Randomization analysis determined that only two examined factors – bone mineral density (BMD) and muscle strength – play a potentially causal role in the risk of suffering osteoporotic fracture. One of the most important findings was that the genetic factors that lead to lowered vitamin D levels do not increase risk of fracture, meaning that vitamin D supplementation is not likely to prevent fractures in the general population. Although vitamin D supplementation is part of clinical guidelines, recent randomized control trials have failed to consistently demonstrate a beneficial effect.Related StoriesStudy: Megakaryocytes play an important role in cell migrationStudy reveals dual effects of new osteoporosis therapy on bone tissueCommon antibacterial agent may be bad news for bone healthAccording to Dr. Kiel, “Among the clinical risk factors for fracture assessed in the study, only BMD showed a major causal effect on fracture. The genetic factors contributing to fractures are also the same ones that affect BMD. Knowing one’s genetic risk for fracture at an early age could be a useful piece of information to persons wanting to maintain their bone health as they age. Also the study identified novel genetic variants that could be used to target future drug therapies to prevent fracture.”Osteoporotic fractures represent a major health risk to older adults: 34 million Americans have low bone density, putting them at increased risk for osteoporosis and broken bones. The condition leads to bone fragility and an increased risk of fractures, especially of the hip, spine and wrist. About one-quarter of those over age 50 who suffer a hip fracture die within a year of the injury. Osteoporosis-related fractures were responsible for an estimated $19 billion in health care costs in 2005, with that figure expected to increase to $25 billion by 2025.